A lower expression of the enzyme methylguanine-DNA-methyltransferase (MGMT) and hypermethylation of its promoter in tumour tissue have been associated with a better response to TMZ in some small studies (1, 14), but these findings have not been validated in larger studies (9–12). The gene discussed is MGMT; the disease is neoplasm.